Through our unique approach to gene science based on Nobel Prize-winning technology, we are moving forward rapidly to bring innovative therapies to market.

We have advanced multiple drug candidates into clinical development. We are presently devoting most of our resources to the development and commercialization of our two most advanced drug candidates, telotristat ethyl for carcinoid syndrome diarrhea and sotagliflozin for type 1 and type 2 diabetes. We have also advanced a number of additional compounds into various stages of clinical and preclinical development.

Sotagliflozin (LX4211)

Sotagliflozin, or LX4211, is an orally-delivered small molecule compound that we are developing for the treatment of type 1 and type 2 diabetes mellitus. Sotagliflozin was internally generated by our medicinal chemists and inhibits both sodium-glucose cotransporter type 2, or SGLT2, a transporter responsible for most of the glucose reabsorption performed by the kidney, and sodium-glucose cotransporter type 1, or SGLT1, a transporter responsible for glucose and galactose absorption in the gastrointestinal tract. Our scientists identified mice lacking SGLT1, SGLT2 or both as having potent anti-diabetic phenotypes across multiple measures of glucose control and metabolism, and found that compounds inhibiting both targets had a favorable preclinical profile relative to compounds selective for SGLT2.

LXRX - Pipeline Progress

Compound Partner Target Indication Preclinical Phase 1 Phase 2 Phase 3 Registration Marketed
Wholly owned (U.S./ Japan) TPH1 Carcinoid Syndrome diarrhea
FDA approval Feb 28, 2017; US launch Mar 01, 2017
Ipsen (ex-U.S./ ex-Japan) TPH1 Carcinoid Syndrome diarrhea
EMA approval Sept 19, 2017; EU launch ongoing
Sotagliflozin (LX4211) Sanofi (WW, ex-Japan) SGLT1/
Type 1 Diabetes (T1DM)
Regulatory Filings Accepted For Review
Sotagliflozin (LX4211) Sanofi (WW, ex-Japan) SGLT1/
Type 2 Diabetes (T2DM)
Phase 3 ongoing
Wholly owned (U.S./ Japan) TPH1 Neuroendocrine tumors (NETs)
Initiating Phase 2
Wholly owned (U.S./ Japan) TPH1 Biliary tract cancer (BTC)
Initiating Phase 2
LX2761 Wholly owned SGLT1
(GI tract)
Phase 1b ongoing
LX9211 Wholly owned AAK1 Neuropathic Pain
Phase 1a ongoing